Paper Details

  1. Home
  2. Paper Details

Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden.

Author: HellquistL, HjorthM, HolmbergE, MagnussonB, RödjerS, WestinJ

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared the effectiveness of two chemotherapy regimens for treating multiple myeloma: melphalan-prednisone (MP) and multi-drug chemotherapy (MDC). The study found no significant difference in response rates, survival times, or time to response between the two groups, regardless of stage. The study concludes that multi-drug chemotherapy does not offer a significant advantage over traditional melphalan-prednisone treatment for multiple myeloma.
Paper Details　
Original Abstract of the Article :
From October 1983 until December 1986, 164 patients with multiple myeloma stage II-III were included in a prospective randomized multi-centre study comparing melphalan-prednisone (MP) with multidrug chemotherapy (MDC). The patients comprised 77% of all newly diagnosed myeloma stage II-III cases repo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1365-2141.1990.tb02564.x

データ提供：米国国立医学図書館（NLM）

Multiple Myeloma: Navigating the Desert of Treatment Options

Multiple myeloma, a cancer of plasma cells in the bone marrow, can be a challenging condition to treat. Imagine the bone marrow as a vast and intricate desert, where cancer cells proliferate and disrupt the delicate balance of healthy cells. This study explores the effectiveness of two different treatment approaches for multiple myeloma: melphalan-prednisone (MP), a traditional combination therapy, and multidrug chemotherapy (MDC). The authors aimed to compare the outcomes of these two treatments in patients with advanced myeloma.

No Clear Advantage: A Tale of Two Paths Through the Desert

The study reveals that there was no statistically significant difference in response rates or survival times between the two treatment arms. It's like discovering two paths through the desert that lead to similar destinations—both can be effective, but one doesn't necessarily outperform the other. The authors emphasize the need for careful consideration of individual patient characteristics and the potential benefits and risks of each treatment option.

Navigating the Desert of Treatment: A Personalized Approach

This study highlights the importance of a personalized approach to cancer treatment, acknowledging that no single therapy works for everyone. The authors underscore the need for careful evaluation of individual patient factors, such as disease stage and overall health, to determine the most appropriate treatment strategy. It's like having a compass and a map to guide your journey through the desert—understanding your surroundings and your capabilities is crucial for making the right choices.

Dr. Camel's Conclusion

This study provides valuable insights into the treatment landscape for multiple myeloma, demonstrating that both traditional and multidrug chemotherapy approaches can be effective. It emphasizes the need for individualized care and careful consideration of patient-specific factors when choosing a treatment plan, ensuring that the chosen path is best suited to the unique challenges of the patient's journey.

Date :
  1. Date Completed 1990-05-03
  2. Date Revised 2019-07-04
Further Info :

Pubmed ID

2180471

DOI: Digital Object Identifier

10.1111/j.1365-2141.1990.tb02564.x

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.